2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.13B.05 Comparison of the Effectiveness of Cisplatin and Carboplatin with Etoposide in Treatment of Small Cell Lung Cancer: Single-center Experience

EP.13B.05 Comparison of the Effectiveness of Cisplatin and Carboplatin with Etoposide in Treatment of Small Cell Lung Cancer: Single-center Experience

Back to course

Pdf Summary

The study conducted by Hasdemir et al. at Baskent University's Department of Medical Oncology evaluated the effectiveness of cisplatin and carboplatin in combination with etoposide in treating small cell lung cancer (SCLC). This single-center, retrospective study analyzed 135 patients, comparing progression-free survival (PFS) and overall survival (OS) between those treated with cisplatin plus etoposide (EP) and those treated with carboplatin plus etoposide (EC). The analysis included both limited and extensive-stage SCLC patients.<br /><br />Key findings of the study highlighted that while cisplatin was more effective regarding OS in limited-stage SCLC patients (31.2 months vs. 20.2 months, p=0.021), there was no significant difference in PFS between the two treatments (16 months vs. 10 months, p=0.133). In contrast, for extensive-stage patients, carboplatin demonstrated a statistically significant advantage in PFS over cisplatin (8 months vs. 7 months, p=0.025), although OS was not significantly different between the two treatment groups (10.8 months vs. 11.3 months, p=0.545).<br /><br />Objective response rates (ORR) in limited stage SCLC were 72% for cisplatin and 83% for carboplatin, while for extensive-stage patients, ORR was nearly identical (96.4% for EP and 96.2% for EC).<br /><br />The study suggests that carboplatin, due to its more tolerable toxicity, and similar efficacy in terms of PFS for extensive-stage patients, may be a preferred choice over cisplatin despite the slight OS advantage of cisplatin in limited-stage SCLC. These insights provide useful guidance in selecting first-line chemotherapy treatments for different SCLC stages.

Asset Subtitle

Ozden Altundag

Meta Tag

Speaker Ozden Altundag

Topic Small Cell Lung Cancer and Neuroendocrine Tumors

Keywords

Hasdemir et al.

Baskent University

Medical Oncology

cisplatin

carboplatin

etoposide

small cell lung cancer

progression-free survival

overall survival

chemotherapy